Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 28

1.

Biofilm production and evaluation of antifungal susceptibility amongst clinical Candida spp. isolates, including strains of the Candida parapsilosis complex.

Melo AS, Bizerra FC, Freymüller E, Arthington-Skaggs BA, Colombo AL.

Med Mycol. 2011 Apr;49(3):253-62. doi: 10.3109/13693786.2010.530032. Epub 2010 Nov 2.

PMID:
21039308
2.

Effect of serum and surface characteristics on Candida albicans biofilm formation.

Frade JP, Arthington-Skaggs BA.

Mycoses. 2011 Jul;54(4):e154-62. doi: 10.1111/j.1439-0507.2010.01862.x. Epub 2010 Mar 11.

PMID:
20337936
3.

Molecular epidemiology of Candida parapsilosis sepsis from outbreak investigations in neonatal intensive care units.

Reissa E, Lasker BA, Iqbal NJ, James M, Arthington-Skaggs BA.

Infect Genet Evol. 2008 Mar;8(2):103-9.

PMID:
18472434
4.

Multilaboratory testing of antifungal combinations against a quality control isolate of Candida krusei.

Chaturvedi V, Ramani R, Ghannoum MA, Killian SB, Holliday N, Knapp C, Ostrosky-Zeichner L, Messer SA, Pfaller MA, Iqbal NJ, Arthington-Skaggs BA, Vazquez JA, Sein T, Rex JH, Walsh TJ.

Antimicrob Agents Chemother. 2008 Apr;52(4):1500-2. doi: 10.1128/AAC.00574-07. Epub 2008 Jan 28.

5.

Paradoxical growth effect of caspofungin observed on biofilms and planktonic cells of five different Candida species.

Melo AS, Colombo AL, Arthington-Skaggs BA.

Antimicrob Agents Chemother. 2007 Sep;51(9):3081-8. Epub 2007 Jun 25.

6.

Multicenter evaluation of a new disk agar diffusion method for susceptibility testing of filamentous fungi with voriconazole, posaconazole, itraconazole, amphotericin B, and caspofungin.

Espinel-Ingroff A, Arthington-Skaggs B, Iqbal N, Ellis D, Pfaller MA, Messer S, Rinaldi M, Fothergill A, Gibbs DL, Wang A.

J Clin Microbiol. 2007 Jun;45(6):1811-20. Epub 2007 Apr 11.

7.

Interlaboratory study of quality control isolates for a broth microdilution method (modified CLSI M38-A) for testing susceptibilities of dermatophytes to antifungals.

Ghannoum MA, Arthington-Skaggs B, Chaturvedi V, Espinel-Ingroff A, Pfaller MA, Rennie R, Rinaldi MG, Walsh TJ.

J Clin Microbiol. 2006 Dec;44(12):4353-6. Epub 2006 Oct 18.

8.

Cryptococcus gattii infection: characteristics and epidemiology of cases identified in a South African province with high HIV seroprevalence, 2002-2004.

Morgan J, McCarthy KM, Gould S, Fan K, Arthington-Skaggs B, Iqbal N, Stamey K, Hajjeh RA, Brandt ME; Gauteng Cryptococcal Surveillance Initiative Group.

Clin Infect Dis. 2006 Oct 15;43(8):1077-80. Epub 2006 Sep 5.

PMID:
16983624
9.

Epidemiology of candidemia in Brazil: a nationwide sentinel surveillance of candidemia in eleven medical centers.

Colombo AL, Nucci M, Park BJ, Nouér SA, Arthington-Skaggs B, da Matta DA, Warnock D, Morgan J; Brazilian Network Candidemia Study.

J Clin Microbiol. 2006 Aug;44(8):2816-23.

10.

Comparison of multilocus sequence typing and Ca3 fingerprinting for molecular subtyping epidemiologically-related clinical isolates of Candida albicans.

Chowdhary A, Lee-Yang W, Lasker BA, Brandt ME, Warnock DW, Arthington-Skaggs BA.

Med Mycol. 2006 Aug;44(5):405-17.

PMID:
16882607
11.

Epidemiology of community-onset candidemia in Connecticut and Maryland.

Sofair AN, Lyon GM, Huie-White S, Reiss E, Harrison LH, Sanza LT, Arthington-Skaggs BA, Fridkin SK.

Clin Infect Dis. 2006 Jul 1;43(1):32-9. Epub 2006 May 30.

PMID:
16758415
12.

Evaluation of amphotericin B interpretive breakpoints for Candida bloodstream isolates by correlation with therapeutic outcome.

Park BJ, Arthington-Skaggs BA, Hajjeh RA, Iqbal N, Ciblak MA, Lee-Yang W, Hairston MD, Phelan M, Plikaytis BD, Sofair AN, Harrison LH, Fridkin SK, Warnock DW.

Antimicrob Agents Chemother. 2006 Apr;50(4):1287-92.

13.

Rapid acquisition of stable azole resistance by Candida glabrata isolates obtained before the clinical introduction of fluconazole.

Borst A, Raimer MT, Warnock DW, Morrison CJ, Arthington-Skaggs BA.

Antimicrob Agents Chemother. 2005 Feb;49(2):783-7.

14.

In vitro evolution of itraconazole resistance in Aspergillus fumigatus involves multiple mechanisms of resistance.

da Silva Ferreira ME, Capellaro JL, dos Reis Marques E, Malavazi I, Perlin D, Park S, Anderson JB, Colombo AL, Arthington-Skaggs BA, Goldman MH, Goldman GH.

Antimicrob Agents Chemother. 2004 Nov;48(11):4405-13.

15.

Epidemiologic and molecular characterization of an outbreak of Candida parapsilosis bloodstream infections in a community hospital.

Clark TA, Slavinski SA, Morgan J, Lott T, Arthington-Skaggs BA, Brandt ME, Webb RM, Currier M, Flowers RH, Fridkin SK, Hajjeh RA.

J Clin Microbiol. 2004 Oct;42(10):4468-72.

16.

Fungemia caused by Zygoascus hellenicus in an allogeneic stem cell transplant recipient.

Brandt ME, Kauffman CA, Pappas PG, Iqbal N, Arthington-Skaggs BA, Lee-Yang W, Smith MT.

J Clin Microbiol. 2004 Jul;42(7):3363-5.

18.

Incidence of bloodstream infections due to Candida species and in vitro susceptibilities of isolates collected from 1998 to 2000 in a population-based active surveillance program.

Hajjeh RA, Sofair AN, Harrison LH, Lyon GM, Arthington-Skaggs BA, Mirza SA, Phelan M, Morgan J, Lee-Yang W, Ciblak MA, Benjamin LE, Sanza LT, Huie S, Yeo SF, Brandt ME, Warnock DW.

J Clin Microbiol. 2004 Apr;42(4):1519-27.

19.

Drug resistance genes and trailing growth in Candida albicans isolates.

Lee MK, Williams LE, Warnock DW, Arthington-Skaggs BA.

J Antimicrob Chemother. 2004 Feb;53(2):217-24. Epub 2003 Dec 19.

PMID:
14688046
20.

Comparative evaluation of NCCLS M27-A and EUCAST broth microdilution procedures for antifungal susceptibility testing of candida species.

Cuenca-Estrella M, Lee-Yang W, Ciblak MA, Arthington-Skaggs BA, Mellado E, Warnock DW, Rodriguez-Tudela JL.

Antimicrob Agents Chemother. 2002 Nov;46(11):3644-7.

21.

Comparison of visual and spectrophotometric methods of broth microdilution MIC end point determination and evaluation of a sterol quantitation method for in vitro susceptibility testing of fluconazole and itraconazole against trailing and nontrailing Candida isolates.

Arthington-Skaggs BA, Lee-Yang W, Ciblak MA, Frade JP, Brandt ME, Hajjeh RA, Harrison LH, Sofair AN, Warnock DW; Candidemia Active Surveillance Group.

Antimicrob Agents Chemother. 2002 Aug;46(8):2477-81.

22.

Candida albicans sterol C-14 reductase, encoded by the ERG24 gene, as a potential antifungal target site.

Jia N, Arthington-Skaggs B, Lee W, Pierson CA, Lees ND, Eckstein J, Barbuch R, Bard M.

Antimicrob Agents Chemother. 2002 Apr;46(4):947-57.

23.

Antifungal drug susceptibility testing and resistance in Aspergillus.

Warnock DW, Arthington-Skaggs BA, Li RK.

Drug Resist Updat. 1999 Oct;2(5):326-334.

PMID:
11504507
24.

In vitro antifungal susceptibility methods and clinical implications of antifungal resistance.

Espinel-Ingroff A, Warnock DW, Vazquez JA, Arthington-Skaggs BA.

Med Mycol. 2000;38 Suppl 1:293-304. Review.

PMID:
11204157
27.

Quantitation of ergosterol content: novel method for determination of fluconazole susceptibility of Candida albicans.

Arthington-Skaggs BA, Jradi H, Desai T, Morrison CJ.

J Clin Microbiol. 1999 Oct;37(10):3332-7.

28.

Positive and negative regulation of a sterol biosynthetic gene (ERG3) in the post-squalene portion of the yeast ergosterol pathway.

Arthington-Skaggs BA, Crowell DN, Yang H, Sturley SL, Bard M.

FEBS Lett. 1996 Aug 26;392(2):161-5.

Supplemental Content

Loading ...
Support Center